Wroclaw, Poland--Can4Med, a licensed wholesale specializing in medical products containing THC and cannabinoids announced in a press release last month that it has obtained Polish authorization to supply medical products and raw materials for cannabis pharmaceutical sales. The company said has signed supply agreement term sheets for up to 100kg a month of high THC oil and flower at competitive rates and is in the process of registering the products in Poland.
Maximilian Weinberg, Founder of Can4Med, said in the press release, "Demand for medical cannabis products is rapidly growing in Poland. While supply constrains and a lack of authorized products has stifled growth in the Polish market, Can4Med can now quickly satisfy doctor and patient demand throughout the country. With an aging population of over 40 million and openness to natural medicine, Poland is the perfect growth opportunity for medical cannabis in Europe."
Can4Med will offer a variety of products, tailored to the needs of its contractors and patients. Over 90% of pharmacies in Poland are ready to dispense medical cannabis prescriptions to patients for indications such as pain management, epilepsy, multiple sclerosis, and the side effects of chemotherapy. Poland's doctors, however, have the freedom to use their own judgment in prescribing cannabis medicine, greatly expanding its usage to treat a wide range of medical problems including mental health conditions such as anxiety and depression. It is estimated that well over 300,000 patients will be eligible to obtain cannabinoid medicine in various forms.
All Can4Med products are approved for sale in Poland and manufactured under GMP (Good Manufacturing Practice) conditions and are subject to constant quality control.